Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-21-005175.pdf
0001558370-21-005175.rtf
0001558370-21-005175.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-21-005262.pdf
0001558370-21-005262.rtf
0001558370-21-005262.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

 View HTML
0001558370-21-004557.pdf
0001558370-21-004557.rtf
0001558370-21-004557.xls
DEFA14A

Additional proxy soliciting materials - definitive

 View HTML
0001558370-21-004559.pdf
0001558370-21-004559.rtf
0001558370-21-004559.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-21-004140.pdf
0001558370-21-004140.rtf
0001558370-21-004140.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-003567.pdf
0001179110-21-003567.rtf
0001179110-21-003567.xls
4/A

Amendment to a previously filed 4

 View HTML
0001179110-21-003568.pdf
0001179110-21-003568.rtf
0001179110-21-003568.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-003005.pdf
0001179110-21-003005.rtf
0001179110-21-003005.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-003003.pdf
0001179110-21-003003.rtf
0001179110-21-003003.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-003009.pdf
0001179110-21-003009.rtf
0001179110-21-003009.xls